Date Added: 14/09/2017

Date Updated: 14/09/2017

Prostate-specific membrane antigen radiopharmaceuticals for metastatic castration-resistant prostate cancer

Specialties: Oncology & radiotherapy - Radiology, imaging & nuclear medicine - Renal disease & urology

Technology Type: Drugs

Stage of development: Investigational - phase III

Stage of EAA: Assessment Complete

Description, patients and keywords:

HealthPACT noted that Lutetium-177 may represent a promising additional treatment option for metastatic castration-resistant prostate cancer. Although studies to date have primarily reported good patient response rates and reductions in prostate specific antigen levels, there is little evidence as to how this translates into improved patient overall survival or quality of life.

HealthPACT considers that further evidence in relation to the patient experience with this treatment and patient outcomes is required before the Lutetium-177 is considered suitable for clinical practice. If Lutetium-177 is further proposed as a complement or substitute to existing treatment standards, high-quality comparative clinical studies will be required.

This report is work in progress and should not be used for external distribution without permission from the originating agency. Users should be aware that reports are based on information available at the time of research and often on a limited literature search.